An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Phamacokinetics of APL-2 in Patients with Warm Antibody Autoimmune Hemolytic Anemia (WAIHA) or Cold Agglutininin Disease (CAD)